AUSTIN, Texas--(BUSINESS WIRE)--Apollo Endosurgery, Inc. (“Apollo”) (NASDAQ:APEN), a leader in less invasive surgical medical devices for bariatric and gastrointestinal procedures, announced the presentation of 20 year outcomes data for the LAP-BAND® System today at the 22nd World Congress of the International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO) in London.
Paul O’Brien, MD and his colleagues reported on the follow up of 8,263 gastric banding patients treated using the LAP-BAND® between September 1994 and June 2017 at the Centre for Bariatric Surgery (CBS) in Melbourne, Australia. Key data reported:
- An overall follow-up rate of 58%.
- Total weight loss for patients out to 20 years was 26.9 kg (59.3 lb), which represents loss of 48.2% of their excess weight.
- The overall explant rate for the entire patient population was 7.9%, with an explant rate of 4.6% for procedures performed in the period between 2006 and 2017, when CBS used the current version of the LAP-BAND® (LAP-BAND® AP Adjustable Gastric Band System).
- In addition, there were no mortalities among all procedures performed, which included primary and re-operation procedures.
These excellent long-term outcomes provide further evidence that LAP-BAND® is a safe and effective procedure that results in sustained, medically relevant weight loss.
Commenting on the results, Dr. O’Brien stated, “The LAP-BAND® is a safe and effective procedure achieving substantial weight loss that can be maintained for at least twenty years. The surgery is simple and can be reversed or corrected easily, but must be technically correct and patients must be managed properly.”
“We congratulate Dr. O’Brien and his colleagues on the great results they have delivered to patients by using the LAP-BAND® system for over two decades. These results demonstrate the kind of long-term results that LAP-BAND® can provide patients in the hands of a bariatric surgeon who is dedicated to long-term patient relationships, treatment and aftercare guidelines,” said Todd Newton, CEO of Apollo Endosurgery. “Dr. O’Brien and his colleagues at CBS epitomize this kind of surgeon.”
About the LAP-BAND®
The LAP-BAND® AP Adjustable Gastric Band System is placed laparoscopically in a minimally invasive procedure to assist in gradual weight loss. The LAP-BAND® System is fastened around the top of the stomach, and works by applying a constant, gentle pressure to this area. This gives you a feeling of satiety (a feeling of fullness) on a smaller amount of food, therefore, you eat less.
LAP-BAND® can deliver sustained weight loss, improvements in quality of life, and reduced cardiometabolic risk when combined with reasonable and proper physician follow-up with their patient.
For additional information regarding LAP-BAND®, please visit lapband.com.
For full safety information please talk with your doctor, or call 1-800-LAPBAND.
About Apollo Endosurgery, Inc.
Apollo Endosurgery, Inc. is a medical device company focused on less invasive therapies for the treatment of obesity, a condition facing over 600 million people globally, as well as other gastrointestinal disorders. Apollo’s device based therapies are an alternative to invasive surgical procedures, thus lowering complication rates and reducing total healthcare costs. Apollo's products are offered in over 60 countries today.
Apollo’s common stock is traded on NASDAQ Global Market under the symbol "APEN." For more information regarding Apollo Endosurgery, go to: apolloendo.com.
© 2017 Apollo Endosurgery, Inc. All rights reserved. Any third-party trademarks used herein are the property of their respective owners.
Cautionary Note on Forward-Looking Statements
Certain statements in this press release are forward-looking statements that are subject to risks and uncertainties that could cause results to be materially different than expectations. Important factors that could cause actual results to differ materially include: price levels for established and innovative medical devices compared to the costs of procedures utilizing our products; developments in medical technology; regulatory approvals; reimbursement decisions by private or government payors or other government actions; physician adoption and recommendations of procedures utilizing our products; and other factors detailed from time to time in the reports Apollo files with the Securities and Exchange Commission, or SEC, including its Form 10-K for the year ended December 31, 2016 and its Form 10-Q for the three months ended June 30, 2017. Copies of reports filed with the SEC are posted on Apollo’s website and are available from Apollo without charge. These forward-looking statements are not guarantees of future performance and speak only as of the date hereof, and, except as required by law, Apollo disclaims any obligation to update these forward-looking statements to reflect future events or circumstances.